Shamburg News · 8-K filed Oct 15, 2026, 4:05 PM EDT

Evofem Biosciences Amends Securities Purchase Agreement with Adjuvant on Convertible Notes

EVFM · Evofem Biosciences, Inc.

  • Material agreement
  • Financing
  • Materiality: medium

On October 9, 2026, Evofem Biosciences, Inc. and Adjuvant Global Health Technology Fund entities entered into a fifth amendment to the Securities Purchase Agreement dated October 14, 2020. The amendment sets the maturity date of the convertible notes to the earliest of December 1, 2026, a change of control at Adjuvant's election, or an accelerated date under Section 8. The notes may not be prepaid before December 1, 2026 without Adjuvant's consent, and certain affirmative covenants in Section 7.1 were removed.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 9.01, accession 0001493152-26-047227.

Written from the filing by Shamburg Markets. Figures are as reported by the company.